FDA Inspection 1193897 — Lavipharm S.A.
The FDA completed an inspection of Lavipharm S.A. on October 19, 2020 in Paiania. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- October 19, 2020
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Paiania (Greece)
Additional Details
Mutual Recognition Agreement (MRA)